Related Experiment Video

Updated: Jul 12, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.5K

STT3A-mediated viral N-glycosylation underlies the tumor selectivity of oncolytic virus M1

Deli Song1,2, Xudong Jia1,2, Yuanzhu Gao1

  • 1State Key Lab for Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, 510275, China.

Oncogene
|October 20, 2023
PubMed

Insights

Oncolytic virus M1 (OVM) requires specific N-glycans for receptor binding and anticancer activity. STT3A enzyme expression predicts OVM therapy effectiveness in solid tumors.

Area of Science:

  • Virology
  • Glycobiology
  • Cancer Therapy

Background:

  • Oncolytic viruses show promise in cancer treatment.
  • The role of N-glycosylation and its enzymes in oncolytic viral therapy is not well understood.

Purpose of the Study:

  • To investigate the role of N-glycans on oncolytic virus M1 (OVM) in receptor binding and oncolysis.
  • To identify the glycan-processing enzyme responsible for OVM N-glycosylation and its potential as a predictive biomarker.

Main Methods:

  • Cryo-electron microscopy (cryo-EM) analysis to identify N-glycans on OVM.
  • Assays to determine the impact of N-glycans on receptor binding (MXRA8).
  • Correlation analysis between STT3A expression and OVM-induced oncolysis in tumor cells.

Main Results:

  • Three distinct N-glycans on OVM were identified as crucial for MXRA8 receptor binding.
  • STT3A, a subunit of oligosaccharyltransferase (OST), was identified as the key enzyme for OVM N-glycosylation.
  • STT3A expression in tumor cells positively correlated with OVM efficacy, and is elevated in various solid tumors.

Conclusions:

  • OVM N-glycosylation is essential for its receptor binding and oncolytic activity.
  • STT3A is a critical determinant of OVM N-glycosylation and a potential predictive biomarker for OVM therapy.
  • OVM demonstrates broad-spectrum anticancer potential, particularly in tumors with increased STT3A expression.

More Related Videos

Engineering Antiviral Agents via Surface Plasmon Resonance13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

2.4K
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.1K

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
538
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K